Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis : A position statement from the Thoracic Society of Australia and New Zealand 2023 revision
© 2024 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology..
Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti-fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non-IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non-pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi-faceted approach to the management of IPF and progressive pulmonary fibrosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Respirology (Carlton, Vic.) - 29(2024), 2 vom: 01. Feb., Seite 105-135 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mackintosh, John A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Idiopathic pulmonary fibrosis |
|---|
| Anmerkungen: |
Date Completed 22.01.2024 Date Revised 22.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/resp.14656 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367025280 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367025280 | ||
| 003 | DE-627 | ||
| 005 | 20240323000542.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/resp.14656 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1341.xml |
| 035 | |a (DE-627)NLM367025280 | ||
| 035 | |a (NLM)38211978 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mackintosh, John A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis |b A position statement from the Thoracic Society of Australia and New Zealand 2023 revision |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.01.2024 | ||
| 500 | |a Date Revised 22.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology. | ||
| 520 | |a Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti-fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non-IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non-pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi-faceted approach to the management of IPF and progressive pulmonary fibrosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a idiopathic pulmonary fibrosis | |
| 650 | 4 | |a interstitial lung disease | |
| 650 | 4 | |a progressive pulmonary fibrosis | |
| 650 | 4 | |a pulmonary fibrosis | |
| 650 | 4 | |a treatment | |
| 650 | 7 | |a Pyridones |2 NLM | |
| 700 | 1 | |a Keir, Gregory |e verfasserin |4 aut | |
| 700 | 1 | |a Troy, Lauren K |e verfasserin |4 aut | |
| 700 | 1 | |a Holland, Anne E |e verfasserin |4 aut | |
| 700 | 1 | |a Grainge, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Chambers, Daniel C |e verfasserin |4 aut | |
| 700 | 1 | |a Sandford, Debra |e verfasserin |4 aut | |
| 700 | 1 | |a Jo, Helen E |e verfasserin |4 aut | |
| 700 | 1 | |a Glaspole, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Wilsher, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Goh, Nicole S L |e verfasserin |4 aut | |
| 700 | 1 | |a Reynolds, Paul N |e verfasserin |4 aut | |
| 700 | 1 | |a Chapman, Sally |e verfasserin |4 aut | |
| 700 | 1 | |a Mutsaers, Steven E |e verfasserin |4 aut | |
| 700 | 1 | |a de Boer, Sally |e verfasserin |4 aut | |
| 700 | 1 | |a Webster, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a Moodley, Yuben |e verfasserin |4 aut | |
| 700 | 1 | |a Corte, Tamera J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respirology (Carlton, Vic.) |d 1998 |g 29(2024), 2 vom: 01. Feb., Seite 105-135 |w (DE-627)NLM093444214 |x 1440-1843 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2024 |g number:2 |g day:01 |g month:02 |g pages:105-135 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/resp.14656 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2024 |e 2 |b 01 |c 02 |h 105-135 | ||